Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Bristol-Myers Squibb (BMY) Share Price
News coverage about Bristol-Myers Squibb (NYSE:BMY) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.6790313749101 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Bristol-Myers Squibb Company (BMY) Receives Consensus Rating of “Hold” from Brokerages (americanbankingnews.com)
- Industry Group Rank Limit Bristol-Myers Squibb Co (BMY) Rating – Investorplace.com (investorplace.com)
- Traders Purchase High Volume of Bristol-Myers Squibb Put Options (BMY) (americanbankingnews.com)
- Novartis on the Street: Analysts’ Recommendations in November (finance.yahoo.com)
Several equities research analysts have recently weighed in on the company. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. SunTrust Banks, Inc. upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. Credit Suisse Group restated a “hold” rating and set a $61.00 target price (up previously from $58.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Piper Jaffray Companies restated a “hold” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Finally, BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $64.93.
Shares of Bristol-Myers Squibb (NYSE:BMY) traded down $0.48 on Monday, hitting $60.84. The company had a trading volume of 2,839,689 shares, compared to its average volume of 8,633,788. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $100,360.00, a P/E ratio of 20.72, a price-to-earnings-growth ratio of 2.42 and a beta of 1.18. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business’s revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.77 earnings per share. sell-side analysts anticipate that Bristol-Myers Squibb will post 2.99 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date of this dividend was Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is 61.42%.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.